Australia’s medical cannabis sector is under fire as health authorities ramp up enforcement against what they call “unsafe” prescribing. More than 57 health professionals are facing regulatory action, with another 60 under investigation — many tied to high-volume telehealth models accused of issuing thousands of cannabis scripts with minimal oversight.
One practitioner allegedly issued 17,000 prescriptions in six months, according to ABC News Australia.
‘Patients Die,’ Says AHPRA — But Where’s the Evidence?
“We have had cases of cannabis-induced psychosis requiring hospitalization. We have had patients die,”
— Martin Fletcher, CEO of AHPRA
While concerns around poor screening are valid — particularly for mental health conditions — no confirmed fatal overdose from cannabis alone has ever been documented in medical literature. Critics argue these claims are unfounded, risk reigniting “Reefer Madness” stigma, and distract from more productive policy goals.
Still, AHPRA is pushing ahead. The agency warns about clinics “coaching” patients through online eligibility forms and has now prohibited prescribing and dispensing cannabis under the same roof, citing conflicts of interest.
New guidelines state cannabis should only be prescribed for conditions with strong clinical evidence — such as epilepsy or chemotherapy-induced nausea — and never as a first-line treatment.
Quality Control or Moral Panic?
While improved standards are widely welcomed, many worry the messaging — especially around death and psychosis — risks derailing cannabis reform through fear-based narratives rather than science.
At the end of the day, it’s not cannabis that’s failing patients. It’s the system around it.
Corporate Violations Add to Scrutiny
In a separate but related development, the Office of Drug Control (ODC) has issued a $19,800 infringement notice to Cannatrek Technologies Pty Ltd, a Queensland-based licensed producer.
According to the ODC, Cannatrek failed to meet its statutory obligations under the Narcotic Drugs Act 1967 by neglecting to report changes in ownership, management, or operational control — a legal requirement for maintaining transparency and compliance in cannabis operations.
The agency emphasized that continued noncompliance could result in civil or criminal proceedings and potential licence suspension or revocation.
A Broader Regulatory Clampdown
The crackdown isn’t limited to rogue clinics or paperwork violations. Major regulatory and professional bodies are closing ranks:
- AHPRA released new prescribing guidance, stating that “seconds-long” consults are unacceptable and doctors must document evaluations, exit plans, and justification for cannabis use.
- The Pharmacy Guild of Australia applauded the enforcement effort and reminded members that cannabis should only be dispensed when there’s clear therapeutic value.
- The Royal Australian & New Zealand College of Psychiatrists (RANZCP) has urged tighter restrictions, especially for high-THC products prescribed for mental health conditions.
- Federal Health Minister Mark Butler criticized for-profit telehealth clinics, calling for reforms to ensure safety without blanket criminalization.
A Fork in the Road
Australia’s medicinal cannabis industry faces a defining moment: raise standards without reviving stigma. While there’s growing consensus around better patient screening and quality control, some fear the current rhetoric risks alienating patients and stalling reform.
Balancing enforcement with evidence-based policy — not moral panic — may be the key to preserving patient access while ensuring public trust.
It’s the system around it.
Photo: Shutterstock
This article is from an external, unpaid contributor. It does not represent High Times’ reporting and has not been edited for content or accuracy.
